Yes, mitral valve prolapse can cause atrial fibrillation, though it does so through indirect structural and electrical remodeling rather than by directly triggering the arrhythmia. The mechanism is a chain reaction: a prolapsing leaflet stretches the left atrium over years, fibrous tissue replaces healthy atrial muscle, and chaotic electrical circuits take hold. Population studies place the lifetime atrial fibrillation risk in prolapse patients at roughly 5 to 15 percent, versus about 2 to 4 percent in the general adult population. The risk is not uniform and concentrates in people with leaflet thickening, left atrial enlargement, or significant mitral regurgitation.
The mechanism: how a floppy valve produces a fibrillating atrium
The mitral valve sits between the left atrium and left ventricle. In prolapse, one or both leaflets bow backward into the atrium during systole because the supporting chordae tendineae are too long or too stretchy. That billowing motion is the anatomical signature, but the arrhythmia story happens one layer deeper.
Each systolic billow exposes the left atrial wall to abnormal mechanical stress. The atrium must also push against a leaking valve when regurgitation is present. Over thousands of cardiac cycles per day, this cyclical stretch activates fibroblasts and promotes collagen deposition. The result is atrial fibrosis, a patchy replacement of flexible muscle with stiff scar tissue.
Fibrotic atrium conducts electricity unevenly. Groups of cells recover at different speeds, so a single premature beat can fragment into multiple wandering wavelets. That is the substrate for atrial fibrillation. The valve lesion is the spark source, and the fibrotic atrium is the dry tinder.
In plain terms: the leaky valve wears out the upper chamber's wiring, and worn wiring short-circuits.
There is a second, faster pathway. Severe mitral regurgitation raises left atrial pressure and volume, stretching the chamber within months rather than decades. Acute atrial stretch shortens the effective refractory period, which makes fibrillation easier to initiate and sustain. This explains why atrial fibrillation can appear suddenly after a chordal rupture, even in a patient with a previously normal rhythm.
How often does it actually happen?
The honest answer is that estimates vary widely because study populations differ. Community-based cohorts that include mostly mild, incidental prolapse report atrial fibrillation prevalence close to the background rate. Referral-center series that see only symptomatic patients report far higher figures. Both are correct for their own populations.
| Study setting | Population | Atrial fibrillation prevalence | Follow-up |
|---|---|---|---|
| Community screening cohort | Mostly mild prolapse, incidental finding | 4 to 6 percent | 5 to 10 years |
| Hospital referral series | Symptomatic prolapse, moderate or greater regurgitation | 12 to 15 percent | 5 to 10 years |
| Severe regurgitation subgroup | Prolapse with flail leaflet or surgical indication | 25 to 30 percent | 5 years |
| General adult population | No prolapse | 2 to 4 percent | Lifetime |
The pattern is consistent: the arrhythmia tracks with regurgitation severity, left atrial size, and age, not with the prolapse diagnosis alone. A 30-year-old with a trace leak and a normal atrium has a risk barely above baseline. A 65-year-old with a thickened leaflet and a left atrium above 40 millimeters has a risk several times higher.
One longitudinal imaging study found that each 5-millimeter increase in left atrial diameter was associated with roughly a 1.4-fold rise in incident atrial fibrillation. That is a meaningful gradient, and it is measurable on a routine echocardiogram.
Who is at highest risk: the variables that matter
Not every prolapse is the same disease. Cardiologists now distinguish classic from non-classic prolapse, and that distinction carries real prognostic weight.
Classic prolapse means leaflet thickness of at least 5 millimeters during diastole. Non-classic prolapse means billowing without thickening. Classic disease is associated with a substantially higher rate of severe regurgitation, endocarditis, and sudden cardiac death, and by extension with more atrial fibrillation.
The risk factors that matter most, in rough order of predictive strength:
- Moderate or severe mitral regurgitation on echocardiography
- Left atrial diameter above 40 millimeters or indexed volume above 34 milliliters per square meter
- Leaflet thickness of 5 millimeters or more (classic prolapse)
- Age above 60 years at diagnosis
- Left ventricular ejection fraction below 50 percent
- Presence of mitral annular disjunction, a separation of the annulus from the ventricular wall
The last item deserves emphasis. Mitral annular disjunction is a non-obvious predictor that appears on imaging in perhaps 20 to 30 percent of classic prolapse cases. It is linked to ventricular arrhythmias and to a higher burden of atrial arrhythmia, and it is frequently missed on a standard read.
The time course: from diagnosis to arrhythmia
Atrial fibrillation in prolapse is usually a late complication, not an early one. The lag between valve diagnosis and first documented arrhythmia is typically measured in years or decades.
| Stage | Typical age range | What happens | Approximate atrial fibrillation risk |
|---|---|---|---|
| Diagnosis | 20s to 40s | Incidental click or murmur, mild billowing | Under 1 percent over 5 years |
| Progressive regurgitation | 40s to 50s | Leaflet thickening, mild to moderate leak, early atrial dilation | 3 to 7 percent over 5 years |
| Established regurgitation | 50s to 60s | Moderate to severe leak, left atrium above 40 millimeters | 12 to 20 percent over 5 years |
| Decompensated phase | 60s and beyond | Severe regurgitation, ventricular dysfunction, surgical referral | 25 to 30 percent over 5 years |
| Post-repair | After surgery | Regurgitation corrected, atrial remodeling partially reverses | Risk falls but does not reach zero |
This timeline is a population average and individual trajectories vary substantially. Some patients never progress past the first stage. Others move quickly because of a flail leaflet or an inherited connective tissue disorder such as Marfan syndrome, in which case atrial fibrillation can appear in the 30s.
Correcting the misconceptions
Several myths persist and are worth dismantling one by one.
Myth one: prolapse itself is an arrhythmia disorder. Prolapse is a structural problem. It is associated with palpitations and with ventricular premature beats, but those are not atrial fibrillation. Conflating the two inflates perceived risk and drives unnecessary anxiety.
Myth two: atrial fibrillation in prolapse always means surgery is imminent. Many patients with prolapse and paroxysmal atrial fibrillation are managed for years with rate control or rhythm control and never reach a surgical threshold. The decision to operate depends on regurgitation severity and ventricular function, not on the rhythm alone.
Myth three: a normal echocardiogram rules out future arrhythmia. A normal echo today says nothing about the atrium in ten years. Progression of regurgitation is the driver, and it can evolve silently.
Myth four: anticoagulation is optional if the prolapse is mild. Stroke risk in atrial fibrillation is driven by the CHA2DS2-VASc score, not by valve severity. A patient with prolapse and a score of 2 or higher needs anticoagulation regardless of how mild the valve lesion is, per the 2023 ACC/AHA atrial fibrillation guideline.
What to actually do: monitoring and management
For a person with known prolapse, the practical strategy is surveillance rather than alarm. Echocardiography every 3 to 5 years is appropriate for mild, asymptomatic disease. Interval shortens to every 1 to 2 years once moderate regurgitation or atrial dilation appears.
Rhythm surveillance matters too. A single 12-lead electrocardiogram captures only a few seconds. For patients with palpitations or an enlarged left atrium, ambulatory monitoring for 24 to 48 hours, or a wearable patch for 7 to 14 days, detects paroxysmal fibrillation that a clinic visit would miss.
Treatment follows standard atrial fibrillation pathways with valve-specific adjustments:
- Rate control with beta-blockers or calcium channel blockers, avoiding agents that worsen ventricular function when ejection fraction is reduced
- Rhythm control with antiarrhythmic drugs or catheter ablation when symptoms persist
- Anticoagulation by CHA2DS2-VASc score, with direct oral anticoagulants generally preferred over warfarin outside mechanical valves
- Early referral for mitral valve repair when regurgitation is severe and symptoms or ventricular dilation appear, since timely repair reduces later arrhythmia burden
Catheter ablation for atrial fibrillation in this population is effective, though recurrence rates run higher than in patients with structurally normal hearts. One meta-analysis of ablation in valve-related atrial fibrillation reported 12-month freedom from recurrence near 60 to 70 percent, compared with 75 to 80 percent in non-valvular cohorts.
Seek urgent evaluation if you notice any of the following red flags:
- Sudden palpitations with chest pain, fainting, or breathlessness at rest
- A resting heart rate above 150 beats per minute that does not settle within minutes
- New one-sided weakness, facial droop, or speech difficulty, which may signal a stroke
- Rapid weight gain of 3 pounds in a day or 5 pounds in a week with leg swelling
Important limitations and open questions
The evidence base has real gaps. Most prolapse cohorts are retrospective and enroll patients decades ago, before modern imaging standardized the diagnosis. Prevalence figures from those studies may overstate risk for today's incidentally detected, mild cases.
The causal direction is also not fully settled. Does prolapse cause atrial fibrillation, or do shared connective tissue abnormalities predispose to both? The two may run in parallel rather than in sequence. Genetic studies of fibrillin and related matrix proteins suggest a common substrate in some families, but this remains a hypothesis rather than an established mechanism.
Finally, atrial fibrillation risk calculators calibrated for the general population do not include prolapse as a variable. Clinicians must therefore individualize using left atrial size, regurgitation grade, and leaflet morphology rather than relying on a single score. That is the current state of the art, and it is a reminder that the answer to "can it cause it" is yes, while the answer to "will it cause it in me" is a probability, not a certainty.